The Paragon Report Provides Equity Research on Dendreon & Cell Therapeutics
NEW YORK, NY, Oct 20, 2011 (MARKETWIRE via COMTEX) -- Drug approvals from administrative bodies in both the U.S. and Europe have been pivotal for biotech companies recently. Investors have been particularly sensitive to decisions made on new drugs considering the state of the global economic recovery. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Dendreon Corporation DNDN -1.45% and Cell Therapeutics, Inc. CTIC -4.07% . Access to the full company reports can be found at:
www.paragonreport.com/DNDN
www.paragonreport.com/CTIC
While there are some success stories in the industry, a number of players are having trouble dealing with the volatile nature of biotechnologies. Research and development costs are extremely high, and the success of a product can sometimes not be measured until late in development. According to Krishan Maggon, a Geneva-based pharmaceuticals consultant, the number of new biotech drugs approved in the U.S. has remained in the 20 to 25 range during the past four years, while in Europe the figure was a record-low 14 last year.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Dendreon’s Provenge is a therapy designed to train a patient’s immune system to fight prostate cancer. Studies indicate it extended patients’ lives by about four months. Recently the FDA approved a third facility where the company will make Provenge.
Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. The company says that its drug candidate Pixantrone, “is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents.”
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
SOURCE: Paragon Financial Limited
